Key statistics
On Thursday, Vaccinex Inc (VCNX:NAQ) closed at 3.60, 158.99% above the 52 week low of 1.39 set on Oct 08, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.70 |
---|---|
High | 3.95 |
Low | 3.37 |
Bid | 3.36 |
Offer | 3.60 |
Previous close | 3.71 |
Average volume | 52.80k |
---|---|
Shares outstanding | 2.80m |
Free float | 2.49m |
P/E (TTM) | -- |
Market cap | 10.37m USD |
EPS (TTM) | -24.59 USD |
Data delayed at least 15 minutes, as of Nov 21 2024 20:59 GMT.
More ▼
- Vaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate Update
- Vaccinex Provides Update on ActivMAb® Platform: Multiple Project Deals and Presentation at SITC
- Vaccinex Reports Improved Immunity Correlating with Clinical Benefit of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer’s Annual Meeting
- Vaccinex Reports New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab at Clinical Trials on Alzheimer’s Disease (CTAD) Conference in Madrid, Spain
- Vaccinex to Report Promising New Efficacy Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab at Clinical Trials on Alzheimer’s Disease (CTAD) Conference on October 31, 2024
- Vaccinex Announces Exercise of Warrants for $6.2 Million in Gross Proceeds
- Vaccinex Provides Update on New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab in Alzheimer’s Disease and Plans to Pursue a Development Partnership
- Vaccinex Reports Positive Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease
- Vaccinex to report topline data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease at the Alzheimer’s Association International Conference, Philadelphia, July 31, 2024
- Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer’s Disease
More ▼